Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 4/20 | 0.53 |
| ▸ | GSK3B | P49841 | 6/20 | 0.38 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.37 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.37 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.36 |
| ▸ | SDHB | P21912 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | STAT3 | P40763 | 1/20 | 0.34 |
| ▸ | STAT1 | P42224 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5382328 | 0.95 | MAPK14 (0.58) | MAPK14GSK3BCSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5391043 | 0.88 | MAPK14 (0.43) | MAPK14GSK3BPTGS2SDHBKDM4E | |
| SCHEMBL5395773 | 0.87 | PTGS2 (0.41) | MAPK14GSK3BPTGS2SDHB | |
| SCHEMBL5379861 | 0.81 | MAPK14 (0.55) | MAPK14GSK3BCSNK1A1CSNK1DCSNK1E | |
| SCHEMBL7163586 | 0.78 | MAPK14 (0.57) | MAPK14GSK3BCSNK1A1CSNK1DCSNK1E | |
| SCHEMBL18963 | 0.78 | NPSR1 (0.49) | PTGS2SDHBKDM4EMITFALDH1A1 | |
| Gw568326X SCHEMBL5391204 | 0.77 | MAPK14 (0.64) | MAPK14GSK3BCSNK1A1CSNK1DCSNK1E | |
| SCHEMBL5385825 | 0.76 | MAPK14 (0.60) | MAPK14GSK3BCSNK1A1CSNK1DCSNK1E | |
| SCHEMBL14593063 | 0.76 | GSK3B (0.55) | MAPK14GSK3BPTGS2 | |
| SCHEMBL5379844 | 0.75 | MAPK14 (0.50) | MAPK14CSNK1A1CSNK1DCSNK1EPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166597-B2 | Fused pyrazole derivatives being protein kinase inhibitors | GLAXO GROUP LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| EP-1311507-B1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LTD (GB) | 2006-03-01 | — | — | EP | disclosed |
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2004-03-18 | — | — | US | disclosed |
| EP-1311507-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2003-05-21 | — | — | EP | disclosed |
| WO-2002016359-A1 | FUSED PYRAZOLE DERIVATIVES BEING PROTEIN KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2002-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040053942-A1 | Fused pyrazole derivatives bieng protein kinase inhibitors | RAF1, SBK3, MAP3K3 | MAPK14 77/4885GSK3B 326/4885CSNK1A1 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.